The Eversense CGM System

The World's Only Long-Term CGM System

With the Eversense 90-Day CGM System, you can actively manage your diabetes simply and with confidence. Eversense provides continuous blood glucose monitoring for up to 90 days via an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.

Sensor Thumbnail


Professionally inserted by your
Health Care Provider.

Remains accurate, even if you sleep on it or while you exercise.1 

Rests comfortably just under the skin.

Learn More
Transmitter Thumbnail


Removable, rechargeable and water resistant.

Sends data every 5 minutes to your mobile device.

Provides on-body alerts even when your mobile device is not nearby.

Learn More
Mobile App Thumbnail

Mobile App

Receive real-time glucose measurements on your compatible mobile phone or smart watch. No need for a separate receiver.

Track events like meals and workouts and see them right on your graph to help identify trends.

Share your data with friends, family and your Health Care Provider.

Learn More

Eversense Sets a New Standard

Improve Diabetes Management

Helps to support better diabetes management.

Pills Icon

Accuracy unaffected when taking Tylenol (Acetaminophen) and/or Vitamin C.2

Radar Icon

Detects 95% of hypoglycemic and 99% of hyperglycemic events.3

Blood Cells Icon

Shown to significantly reduce A1c by 0.5%.1

Device Icon

Transmitter can be removed and replaced without wasting the sensor.


It’s not just about the data, it’s about the freedom it’s given me.

Matt, Eversense CGM User

Learn Why Matt Loves Eversense*

* The individual in this video has been sponsored by Senseonics to appear in the video. The opinions expressed belong solely to the individual. This information provides general information only. It is not intended to be used as medical advice, diagnosis or treatment and should not replace the advice of a Health Care Provider. A Health Care Provider must be consulted and the device user manual reviewed in full before use. Individual results may vary, testimonials are not claimed to represent typical results. All testimonials are not intended to represent or guarantee that anyone will achieve the same or similar results

  1. Christiansen MP, Klaff LJ, Brazg R, et al. A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II. Diabetes Technology & Therapeutics. 2018; 20(3): 197–206
  2. Lorenz C, Sandoval W, Mortellaro M. Interference Assessment of Various Endogenous and Exogenous Substances on the Performance of the Eversense Long-Term Implantable Continuous Glucose Monitoring System. Diabetes Technology and Therapeutics. 2018; 20(5): 344-352. DOI: 10.1089/dia.2018.0028
  3. Christiansen MP, KlaffLJ, Bailey TS, Brazg R, Carlson G, Tweden KS. A Prospective Multicenter Evaluation of the Accuracy and Safety of an Implanted Continuous Glucose Sensor: The PRECISION Study. Diabetes Technology & Therapeutics. 2019; 21(5): 231 -237. doi:10.1089/dia.2019.0020.

The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of such marks by Ascensia Diabetes Care is under license.